Clinical Trial Update: The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2586881 in patients with acute lung injury; study completed with post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Injury

Drugs mentioned

• GSK2586881

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lung Injury, Acute | Phase 2 | Status: COMPLETED | Results posted: 2017-09-28